account_id none on file
legal_name AEON Biopharma, Inc.
ticker AEON
cik 1837607
domain aeonbiopharma.com
linkedin_company_url https://www.linkedin.com/company/aeon-biopharma-inc/
entry_point_account_id none on file
name AEON Biopharma Inc.
exchange NYSE
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 11 executives 4 family 0
why_nownone on file
callsnone on file
filings
Other SG&A expenses include travel expenses, market research and analysis, conferences and trade shows, professional services fees, including legal, audit and tax fees, insurance costs, general corporate expenses, and allocated facilities-related expenses.
filing / Aug 12, 2026 / receipt
Additionally, research and development expenses include employee compensation, including stock-based compensation, supplies, consulting, prototyping, testing, materials, travel expenses and an allocation of facility overhead expenses.
filing / Aug 12, 2026 / receipt
The decrease in SG&A expenses was primarily attributable to a decrease in professional and legal fees in the second quarter of 2026 compared to the second quarter of 2025, slightly offset by increases in payroll-related expenses including accrued compensation expense in the current year compared to prior year and an increase in headcount in 2026 compared to the prior year.
filing / Aug 12, 2026 / receipt
In July 2026, the Company entered into a non-cancellable lease agreement for new office space located in Aliso Viejo, California.
filing / Aug 12, 2026 / receipt
In December 2021, the Company entered into a three-year non-cancellable lease for office space. The lease was extended for an additional five years in March 2024.
filing / Aug 12, 2026 / receipt
In the second quarter of 2026, the Company entered into a sublease agreement for its existing corporate office space. Under the terms of the sublease, the subtenant is expected to take occupancy in the third quarter of 2026, subject to customary conditions.
filing / Aug 12, 2026 / receipt
Other SG&A expenses include travel expenses, market research and analysis, conferences and trade shows, professional services fees, including legal, audit and tax fees, insurance costs, general corporate expenses, and allocated facilities-related expenses.
filing / May 14, 2026 / receipt
Additionally, research and development expenses include employee compensation, including stock-based compensation, supplies, consulting, prototyping, testing, materials, travel expenses and an allocation of facility overhead expenses.
filing / May 14, 2026 / receipt
On March 6, 2026, the Company’s board of directors appointed John Bencich as the Company’s Chief Financial Officer, effective as of March 9, 2026 and principal financial officer, effective as of April 1, 2026.
filing / May 14, 2026 / receipt
In December 2021, the Company entered into a three-year non-cancellable lease for office space. The lease was extended for an additional five years in March 2024.
filing / May 14, 2026 / receipt
In April 2026, the Company entered into a sublease agreement for its existing corporate office space, which was finalized with landlord consent in May 2026.
filing / May 14, 2026 / receipt
executives
| Jennifer Sy | Chief Accounting Officer | receipt | |
| John Bencich | Chief Financial Officer | receipt | |
| Jost Fischer | President & CEO, Board Member | - | receipt |
| Robert Bancroft | Principal Executive Officer | - | receipt |
familynone on file
upcoming
| 2026-11-13 | earnings call | scheduled | ir |
changes
| 2026-03-09 | Chief Financial Officer, appointed | sec_8k |
| 2025-04-21 | Interim President and Chief Executive Officer, departed | sec_8k |
| 2025-04-21 | Principal Executive Officer, appointed | sec_8k |
| 2025-04-08 | Chief Accounting Officer, appointed | sec_8k |
| 2025-04-08 | Interim Chief Executive Officer, appointed | sec_8k |
| 2025-03-27 | Interim CEO, appointed | sec_8k |
mcp_package_hint
slug aeon-biopharma-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$